387

• NanoViricides, Inc. (NYSE American: NNVC) received regulatory approval on August 10, 2026, to launch a Phase II clinical trial for its NV-387 oral gummies. • The trial will take place in the Democratic Republic of Congo to treat patients affected by the current largest and most rapidly expanding Ebola outbreak. • This development is critical as the company aims to provide an accessible, antiviral treatment designed to prevent viral escape during a public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies, designed as a treatment for the Ebola virus. • The trial will take place in the Democratic Republic of Congo to combat the largest and most rapidly expanding Ebola outbreak on record. • The urgency for the treatment is heightened by the virus spreading into displacement camps housing over 4.4 million people, where poor sanitation and medical resources increase risk.

• NanoViricides has received approval from the National Ethics Committee in the Democratic Republic of Congo to conduct a Phase II trial of NV-387. • The trial will test the efficacy of NV-387 oral gummies specifically designed to treat the Bundibugyo strain of the Ebola virus. • The company is now preparing the necessary regulatory filings for ACOREP to move the clinical study forward.

Analysis commissioned by independent senator found national science agency’s funding is at its lowest since 1978Get our breaking news email, free app or daily news podcastThe Albanese government will boost funding to CSIRO by $387.4m in a bid to meet the long-term costs of the national science agency.It follows months of advocacy by scientists and staff after hundreds of job cuts and cost-cutting measures. Continue reading...